JP2000514420A - 末梢または中枢神経障害およびサイトカイン過剰産生の治療のためのｋ―２５２ａ誘導体の使用 - Google Patents

末梢または中枢神経障害およびサイトカイン過剰産生の治療のためのｋ―２５２ａ誘導体の使用

Info

Publication number
JP2000514420A
JP2000514420A JP10503444A JP50344498A JP2000514420A JP 2000514420 A JP2000514420 A JP 2000514420A JP 10503444 A JP10503444 A JP 10503444A JP 50344498 A JP50344498 A JP 50344498A JP 2000514420 A JP2000514420 A JP 2000514420A
Authority
JP
Japan
Prior art keywords
compound
formula
mammal
disease
neurons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP10503444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000514420A5 (enExample
Inventor
エングバー，トーマス・エム
ホーン，フォレスト・エイ
サポリト，マイケル・エス
エイモーン，リサ・ディ
ミラー，マシュー・エス
ナイト，アーネスト・ジュニア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21798468&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2000514420(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon LLC filed Critical Cephalon LLC
Publication of JP2000514420A publication Critical patent/JP2000514420A/ja
Publication of JP2000514420A5 publication Critical patent/JP2000514420A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP10503444A 1996-06-25 1997-06-24 末梢または中枢神経障害およびサイトカイン過剰産生の治療のためのｋ―２５２ａ誘導体の使用 Pending JP2000514420A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2040696P 1996-06-25 1996-06-25
US60/020,406 1996-06-25
PCT/US1997/010898 WO1997049406A1 (en) 1996-06-25 1997-06-24 Use of k-252a derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008053174A Division JP4767982B2 (ja) 1996-06-25 2008-03-04 末梢または中枢神経障害およびサイトカイン過剰産生の治療のためのｋ−２５２ａ誘導体の使用

Publications (2)

Publication Number Publication Date
JP2000514420A true JP2000514420A (ja) 2000-10-31
JP2000514420A5 JP2000514420A5 (enExample) 2005-02-10

Family

ID=21798468

Family Applications (2)

Application Number Title Priority Date Filing Date
JP10503444A Pending JP2000514420A (ja) 1996-06-25 1997-06-24 末梢または中枢神経障害およびサイトカイン過剰産生の治療のためのｋ―２５２ａ誘導体の使用
JP2008053174A Expired - Lifetime JP4767982B2 (ja) 1996-06-25 2008-03-04 末梢または中枢神経障害およびサイトカイン過剰産生の治療のためのｋ−２５２ａ誘導体の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008053174A Expired - Lifetime JP4767982B2 (ja) 1996-06-25 2008-03-04 末梢または中枢神経障害およびサイトカイン過剰産生の治療のためのｋ−２５２ａ誘導体の使用

Country Status (16)

Country Link
US (1) US6184217B1 (enExample)
EP (1) EP0912184B1 (enExample)
JP (2) JP2000514420A (enExample)
CN (1) CN1108799C (enExample)
AT (1) ATE224718T1 (enExample)
AU (1) AU721942B2 (enExample)
BR (1) BR9710693A (enExample)
DE (1) DE69715862T2 (enExample)
DK (1) DK0912184T3 (enExample)
ES (1) ES2184106T3 (enExample)
NO (1) NO317335B1 (enExample)
NZ (1) NZ333441A (enExample)
PT (1) PT912184E (enExample)
RU (1) RU2183959C2 (enExample)
UA (1) UA65542C2 (enExample)
WO (1) WO1997049406A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000290184A (ja) * 1999-04-01 2000-10-17 Kyowa Hakko Kogyo Co Ltd 経鼻投与製剤
JP2009544703A (ja) * 2006-07-24 2009-12-17 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓｐ３５またはＴｒｋＡアンタゴニストの投与により髄鞘形成、ニューロンの生存および希乏突起膠細胞の分化を促進するための方法
US9745375B2 (en) 2008-07-09 2017-08-29 Biogen Ma Inc. Compositions comprising antibodies to LINGO or fragments thereof
US9796780B2 (en) 2012-05-14 2017-10-24 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
US10435467B2 (en) 2015-01-08 2019-10-08 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
CA2345295C (en) 1998-09-25 2009-12-15 Cephalon, Inc. Use of fused pyrrolocarbazoles in preventing/treating damage to sensory hair cells and cochlear neurons
MXPA01003761A (es) 1998-10-13 2003-07-21 Kyowa Hakko Kogyo Kk Agente para tratar oftalmopatia.
CA2396165C (en) * 2000-01-14 2011-01-04 John F. Hunt Airway alkalinization as therapy for airway diseases
AU2001261324A1 (en) * 2000-05-08 2001-11-20 Psoriasis Research Institute Psoriasis treatment
US7129250B2 (en) 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
US7018999B2 (en) 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
WO2004058190A2 (en) * 2002-12-23 2004-07-15 Rinat Neuroscience Corp. Methods for treating taxol-induced sensory neuropathy
PL1606409T3 (pl) 2003-03-19 2011-02-28 Biogen Ma Inc Białko wiążące receptor Nogo
JP2006520806A (ja) * 2003-03-20 2006-09-14 ライナット ニューロサイエンス コーポレイション タキソール誘導性腸障害を処置する方法
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
EP1646372A2 (en) * 2003-07-14 2006-04-19 Decode Genetics EHF. Methods of diagnosis and treatment for asthma based on haplotype association
US20060014165A1 (en) * 2003-07-14 2006-01-19 Decode Genetics Ehf. Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
WO2005014003A1 (en) * 2003-07-23 2005-02-17 Creabilis Therapeutics S.R.L. Topical use of tyrosine kinase inhibitors of microbial origin to prevent and treat skin disorders characterised by excessive cell proliferation
WO2005082920A1 (en) 2004-02-27 2005-09-09 H. Lundbeck A/S Crystalline forms of a pharmaceutical compound
PL1776136T3 (pl) 2004-06-24 2013-03-29 Biogen Ma Inc Leczenie stanów związanych z demielinizacją
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
AR054260A1 (es) * 2005-04-26 2007-06-13 Rinat Neuroscience Corp Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos
SG10201508322SA (en) 2005-07-08 2015-11-27 Biogen Ma Inc Sp35 antibodies and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041489A (ja) * 1983-08-12 1985-03-05 Kyowa Hakko Kogyo Co Ltd 新規生理活性物質ｋ―２５２
US4554402A (en) 1983-12-23 1985-11-19 Aluminum Company Of America Vibration damper for overhead conductor
JPS62120388A (ja) 1985-11-19 1987-06-01 Meiji Seika Kaisha Ltd Ｓｆ−２３７０物質ハロゲン化誘導体とその製造法
JPS62155284A (ja) 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPS62155285A (ja) 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPS62220196A (ja) 1986-03-20 1987-09-28 Kyowa Hakko Kogyo Co Ltd 新規物質ｕｃｎ―０１
US4816450A (en) 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
JPH0826036B2 (ja) 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
US4735939A (en) 1987-02-27 1988-04-05 The Dow Chemical Company Insecticidal activity of staurosporine
EP0303697B1 (en) 1987-03-09 1997-10-01 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance k-252
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JPH07113027B2 (ja) 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
WO1989007105A1 (fr) 1988-02-04 1989-08-10 Kyowa Hakko Kogyo Co., Ltd. Derives de staurosporine
DE3835842A1 (de) 1988-10-21 1990-04-26 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE3924538A1 (de) 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung
AU7035991A (en) 1989-12-14 1991-07-18 Schering Corporation Indolocarbazoles from saccharothrix aerocolonigenes subsp. copiosa subsp. nov. scc 1951 atcc 53856
JPH0586068A (ja) 1991-03-04 1993-04-06 Rikagaku Kenkyusho 新規抗生物質ｒｋ−１４０９、その製造法並びに抗腫瘍剤及び抗炎症剤
WO1993008809A1 (en) 1991-11-08 1993-05-13 The University Of Southern California Compositions containing k-252 compounds for potentiation of neurotrophin activity
JP2593021B2 (ja) 1991-12-13 1997-03-19 伊藤ハム株式会社 ウシ胚の性の識別方法
RU2045575C1 (ru) * 1992-01-29 1995-10-10 Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов Рекомбинатная плазмидная днк ppr - tgatg - hil - 1 beta - tsr, обеспечивающая синтез рекомбинантного интерлейкина-1 и штамм escherichia coli - продуцент рекомбинантного интерлейкина-1 бета человека
US6271242B1 (en) 1992-02-10 2001-08-07 Bristol-Myers Squibb Co. Method for treating cancer using a tyrosine protein kinase inhibitor
JPH05247055A (ja) 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
US5344926A (en) 1992-06-22 1994-09-06 Kyowa Hakko Kogyo Co., Ltd. Process for producing staurosporine derivatives
JPH0673063A (ja) 1992-06-22 1994-03-15 Kyowa Hakko Kogyo Co Ltd Ｕｃｎ−０１誘導体
US5621100A (en) 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
GB9215921D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Anti-inflammatory compounds
EP0839814A3 (en) 1993-05-28 1998-09-16 Cephalon, Inc. Indolocarbazole derivatives and their use for the treatment of prostate gland disorders
JPH08511785A (ja) 1993-06-17 1996-12-10 チバ−ガイギー アクチェンゲゼルシャフト プロテインキナーゼｃ阻害剤として有用なインドロカルバゾール
WO1995022331A1 (en) * 1994-02-18 1995-08-24 Cephalon, Inc. Aqueous indolocarbazole solutions

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000290184A (ja) * 1999-04-01 2000-10-17 Kyowa Hakko Kogyo Co Ltd 経鼻投与製剤
JP2009544703A (ja) * 2006-07-24 2009-12-17 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓｐ３５またはＴｒｋＡアンタゴニストの投与により髄鞘形成、ニューロンの生存および希乏突起膠細胞の分化を促進するための方法
US8642040B2 (en) 2006-07-24 2014-02-04 Biogen Idec Ma Inc. Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of Sp35 or TrkA antagonists
US9745375B2 (en) 2008-07-09 2017-08-29 Biogen Ma Inc. Compositions comprising antibodies to LINGO or fragments thereof
US9796780B2 (en) 2012-05-14 2017-10-24 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
US10435467B2 (en) 2015-01-08 2019-10-08 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders

Also Published As

Publication number Publication date
EP0912184B1 (en) 2002-09-25
NO986111L (no) 1999-02-23
WO1997049406A1 (en) 1997-12-31
CN1228024A (zh) 1999-09-08
NO317335B1 (no) 2004-10-11
CN1108799C (zh) 2003-05-21
HK1018745A1 (en) 2000-01-07
ATE224718T1 (de) 2002-10-15
RU2183959C2 (ru) 2002-06-27
BR9710693A (pt) 2000-01-11
ES2184106T3 (es) 2003-04-01
DE69715862T2 (de) 2003-04-10
JP4767982B2 (ja) 2011-09-07
EP0912184A1 (en) 1999-05-06
DK0912184T3 (da) 2002-11-25
UA65542C2 (uk) 2004-04-15
PT912184E (pt) 2002-12-31
JP2008189676A (ja) 2008-08-21
US6184217B1 (en) 2001-02-06
DE69715862D1 (de) 2002-10-31
NO986111D0 (no) 1998-12-23
AU3409097A (en) 1998-01-14
AU721942B2 (en) 2000-07-20
NZ333441A (en) 1999-05-28

Similar Documents

Publication Publication Date Title
JP4767982B2 (ja) 末梢または中枢神経障害およびサイトカイン過剰産生の治療のためのｋ−２５２ａ誘導体の使用
Nguyen et al. Sigma-1 receptors and neurodegenerative diseases: towards a hypothesis of sigma-1 receptors as amplifiers of neurodegeneration and neuroprotection
Akyuz et al. An expanded narrative review of neurotransmitters on Alzheimer’s disease: the role of therapeutic interventions on neurotransmission
KR20100014392A (ko) 섬유근통 치료용 드록시도파 및 약학 조성물
Hao et al. Bioengineered microglia-targeted exosomes facilitate Aβ clearance via enhancing activity of microglial lysosome for promoting cognitive recovery in Alzheimer's disease
Green et al. The inhibitory effect of intraventricular administration of serotonin on spontaneous motor activity of rats
KR20220142477A (ko) 인지 저하 환자에서 아밀로이드 베타 단량체 수준을 감소시키는 방법
Rylkova et al. Effects of NPY and the specific Y1 receptor agonist [D-His26]-NPY on the deficit in brain reward function and somatic signs associated with nicotine withdrawal in rats
US20130017274A1 (en) Low dose lithium in the treatment or prophylaxis of parkinson's disease
IL305528A (en) Combinations of opioids and acylethnoamines
WO2018235016A1 (en) A composition for treatment or prevention of a neurodegenerative disease
Bassi et al. Dopamine receptors and sleep induction in man.
KR102693607B1 (ko) 하지 불안 증후군을 치료하기 위한 치료제
Park et al. Honokiol-induced SIRT3 upregulation protects hippocampal neurons by suppressing inflammatory processes in pilocarpine-induced status epilepticus
KR100794204B1 (ko) 신경 친화성 타크로리무스 유사체
WO2020110128A1 (en) Combination of pridopidine and an additional therapeutic agent for treating drug induced dyskinesia
KR100479362B1 (ko) 중추또는말초신경계장애및싸이토카인과잉생산치료를위한k-252a유도체
JPH08504203A (ja) パーキンソン病およびその進行を治療する薬剤の製造のためのイダゾキサンおよびその誘導体の使用
WO2008010768A1 (en) Method of treating and diagnosing restless legs syndrome and periodic limb movements during sleep and means for carrying out the method
RU2841658C1 (ru) Способ снижения уровней мономеров бета-амилоида у пациентов со снижением когнитивных способностей
Brailowsky et al. Acceleration of functional recovery from motor cortex ablation by two Ginkgo biloba extracts in rats
Kucinski et al. Unilateral 6-OHDA th-fgfr1 (tk-) mouse model supports the role of FGFs in Parkinson’s disease and the effects of nicotine and L-DOPA on spontaneous motor impairments
JPH09500375A (ja) パーキンソン病の治療を目的とする医薬品の製造のためのエファロキサンおよびその誘導体の使用
CN113041240B (zh) Act001在制备治疗帕金森药物和治疗nlrp3炎症小体介导的神经炎药物上的应用
MXPA99000278A (en) Use of derivative of k-252a for the treatment of central peripheral nerve disorders and citoqu overproduction

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080205

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090519

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091006